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Abstract
Background: Flavones found in plants display various biological activities, including anti-allergic, anti-viral,
anti-inflammatory, anti-oxidation, and anti-tumor effects. In this study, we investigated the anti-tumor effects of flavone,
apigenin and luteolin on human breast cancer cells.
Methods: The anti-cancer activity of flavone, apigenin and luteolin was investigated using the MTS assay. Apoptosis was
analyzed by Hoechst 33342 staining, flow cytometry and western blot. Cell migration was determined using the culture
inserts and xCELLigence real-time cell analyzer instrument equipped with a CIM-plate 16. Real-time quantitative PCR and
western blot were used to determine the signaling pathway elicited by flavone, apigenin and luteolin.
Results: Flavone, apigenin and luteolin showed potent inhibitory effects on the proliferation of Hs578T, MDA-MB-231
and MCF-7 breast cancer cells in a concentration and time-dependent manner. The ability of flavone, apigenin and
luteolin to inhibit the growth of breast cancer cells through apoptosis was confirmed by Hoechst33342 staining and
the induction of sub-G1 phase of the cell cycle. Flavone, apigenin and luteolin induced forkhead box O3 (FOXO3a)
expression by inhibiting Phosphoinositide 3-kinase (PI3K) and protein kinase B (PKB)/Akt. This subsequently elevated
the expression of FOXO3a target genes, including the Cyclin-dependent kinase inhibitors p21Cip1 (p21) and p27kip1 (p27),
which increased the levels of activated poly(ADP) polymerase (PARP) and cytochrome c.
Conclusion: Taken together, these data demonstrated that flavone, apigenin and luteolin induced cell cycle arrest and
apoptosis in breast cancer cells through inhibiting PI3K/Akt activation and increasing FOXO3a activation, which suggest
that flavone, apigenin and luteolin will be the potential leads for the preventing and treating of breast cancer.
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Background
Breast cancer is one of the most common types of can-
cer affecting women in western countries, and in recent
years, the number of deaths caused by breast cancer has
been increasing in Taiwan. Despite the new promising
breakthrough in therapeutics, the annual breast cancer
mortality rate continues to increase, and one million
new cases are diagnosed every year [1]. Numerous risk
factors for breast cancer etiology have been identified,
including genetic, gender, age, alcohol consumption,
smoking and obesity [2–5].
Breast cancer develops as a consequence of cellular
changes that increase the rate of cell division and
metastasis, decrease the rate of apoptosis, or both. These
changes often involve dysregulation of key signal trans-
duction pathways within the cell that transmit extra-
cellular signals to transcription factors, resulting in
changes in gene expression. Previous studies have
shown that increased protein kinase B (PKB)/Akt activity
can promote breast cancer cell survival and therapeutic
resistance [6, 7]. Forkhead box O3 (FOXO3a), a down-
stream target of the phosphatidylinositol-3-kinase
(PI3K)/Akt pathway, belongs to a family of transcrip-
tion factors that are characterized by a distinct fork-
head DNA-binding domain [8]. Activation of PI3K/Akt
signaling causes phosphorylation of FOXO3a, thereby
inhibiting its activity and translocating it out of the nu-
cleus, where it becomes subject to proteasomal degrad-
ation in the cytosol [9]. The cytoplasmic expression
level of FOXO3a is correlated with Akt phosphorylation
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and is associated with poor prognosis in breast cancer
[10]. Nuclear localization of FOXO3a promotes the ex-
pression of multiple target genes such as p21Cip1 (p21),
p27kip1 (p27), and cyclin D, which results in cell cycle
arrest to inhibit the growth of cancer cells [9, 11, 12].
Cell cycle arrest in the G1, G2-M, and S phases can lead to
apoptosis [13, 14]. FOXO transcription factors are also in-
volved in the cellular stress response, and they regulate cell
cycle progression and apoptosis [15]. In particular, FOXO3a
plays a vital role in the initiation of cell cycle arrest, in
addition to its involvement in DNA damage-mediated
apoptosis [16]. Moreover, FOXO3a is an important tumor
suppressor that is underexpressed in many breast cancers.
Several anti-cancer drugs have been shown to increase the
expression of FOXO3a, which suggest it is a tangible thera-
peutic target for breast cancer therapy [17].
Surgical resection, radiation therapy, and chemotherapy
are among the main treatment options for breast cancer
patient. In addition, there is growing need to discover new
chemopreventive agents that are effective in preventing/
treating breast cancer. Polyphenols are compounds found
in food plants and Chinese herbs, and they can be divided
into various classes on the basis of their molecular struc-
ture. Flavonoids constitute a class of polyphenols that can
be further divided into the following six subclasses: fla-
vones, flavanones, flavanols, flavonols, flavonols, isofla-
vones, and anthocyanidins [18, 19]. A recent study
showed that flavonoids exhibit various beneficial biological
properties such as anti-inflammatory [20, 21], anti-viral
[22, 23], anti-allergic [24], anti-oxidant, [25, 26] and anti-
tumor activities [27–31]. Researchers have also discovered
that flavones inhibit tumor growth by promoting apop-
tosis in cancer cells [27, 28, 32]. Compounds in the fla-
vone subclass, including flavone, apigenin, and luteolin,
are present in fruits and vegetables and are considered to
be potent dietary phytochemicals that are effective in can-
cer chemoprevention [33, 34].
Although different mechanisms and signaling pathways
have been proposed as targets of flavone, apigenin, and
luteolin, these compounds were studied individually and
occasionally by using different model cancer cells. How-
ever, whether these structurally similar compounds could
induce common pathways among different types of cancer
cells to potentiate their chemoprevention activity remains
to be elucidated. The objectives of the present study were
to investigate the anti-proliferative role of flavone, api-
genin, and luteolin in MCF-7, Hs578T, and MDA-MB-231
human breast cancer cells, and to elucidate the common
molecular pathways in these cells.
Methods
Cell culture
The human Breast cancer cell lines Hs578T, MDA-MB-231
and MCF-7 were purchased from American Type Culture
Collection. Cells were cultured in Dulbecco’s modified
Eagle medium (Invitrogen), supplemented with 10 % fetal
bovine serum (Invitrogen) and 1 % penicillin-streptomycin
solution (Invitrogen) at 37 °C in a 5 % CO2 incubator. No
approvals were required for this study, which complied with
all relevant regulations.
Cell viability assay
Cell viability was determined using the MTS/PMS ((3-
(4,5-dimethylthiazol-2-yl)-5-(3-carboxymethoxyphenyl)-2
(4-sulfophenyl)-2H-tetrazolium, inner salt)/phenazine
methosulfate) assay. Hs578T (2 × 103 cells/well), MDA-
MB-231 (2 × 103 cells/well) and MCF-7 (4 × 103 cells/well)
cells were seeded in 96-well plates. Media containing dif-
ferent concentrations (0–100 μM) of the flavone (HPLC >
98 %, Sigma), apigenin (HPLC > 95 %, Sigma) and luteolin
(TLC > 98 %, Sigma) were added and incubated for 72 h.
Subsequently, 20 μl of MTS was added from a stock
solution (2 mg/mL) and incubated for an additional
2 h. The absorbance was read at 490 nm in the micro-
plate reader 550 model (Bio-rad).
Hoechst 33342 staining for detection of cell apoptosis
Apoptosis was analyzed by Hoechst 33342 staining. The
MCF-7, Hs578T, and MDA-MB-231 cells were seeded in
6-well plates (2 × 105 cells/well) and treated with IC50 con-
centrations (Table 1) of flavone, apigenin and luteolin for
24 h. Cells were stained with 40 mg/mL Hoechst 33342
(Sigma). Nuclear morphology was assessed using the cell
membrane penetration DNA dye Hoechst 33342. Then,
the cells were visualized under a fluorescence microscope
with a blue filter.
Cell cycle analysis
For cell cycle analysis, cells were seeded in a 10-cm dish
(5 × 105 cells) and allowed to adhere overnight. Cells
were then treated with IC50 concentrations (Table 1) of fla-
vone, apigenin and luteolin for 24 h. Cells were harvested
and fixed in ice-cold 70 % ethanol overnight at −20 °C.
Cells were washed with ice-cold PBS and subsequently
suspended in staining buffer (20 μg/mL propidium
iodide; 0.1 % Tween 20; 0.2 mg/mL RNase A in PBS),
and incubated at room temperature for 30 min. Using
flow cytometry (FACSort instrument and analysis soft-
ware; ModFit LT), the cells were analyzed with regard
to cell cycle distribution and apoptosis.
Colony formation assay
Cells were plated in a 25 T flask at a density of 2 × 103
cells and treated with IC50 concentrations (Table 1) of
flavone, apigenin and luteolin for 21 d. Thereafter, the
cells were then fixed with methanol for 15 min, followed
by incubation with 0.5 % crystal violet for 30 min and
rinsing with deionized distilled water.
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Wound healing assay
Cell migration was determined using the culture inserts
(ibidi). Cells were then trypsinized, counted, plated into
each well of the culture-inserts (3.5 × 104 cells per well),
and incubated at 37 °C in a humidified atmosphere with
5 % CO2. Cells were allowed to attach for 12 h, and then
the culture inserts were gently removed. MCF-7 breast
cancer cells were treated with flavone (88 μM), apigenin
(30 μM), and luteolin (43 μM) for 24 h. Images were
processed and analyzed using Image Plus software.
Analysis of cell migration and invasion
To monitor cell migration/invasion in real time, we
used the xCELLigence Real-Time Cell Analyzer (RTCA)
DP Instrument equipped with a CIM-plate 16 (Roche,
Indianapolis, IN), which is a 16-well system in which each
well is composed of upper and lower chambers separated
by an 8-μm microporous membrane. Migration/invasion
was measured as the relative impedance change (cell
index) across microelectronic sensors integrated into the
bottom side of the membrane. For cell migration experi-
ments, cells (7.5 × 104 /well) were added in duplicates to
the upper chambers. MCF-7 breast cancer cells were
treated with flavone (88 μM), apigenin (30 μM) and luteo-
lin (43 μM). Migration/invasion was monitored every hour
for 9 h. For quantification, the cell index at the indi-
cated time points was averaged from three independent
measurements.
RNA extraction, reverse transcription (RT), and
real-time PCR
Total RNA from Hs578T, MDA-MB-231 and MCF-7
cells was extracted using the RNeasy Mini Kit (Qiagen,
Valencia, CA). RNA (4 μg) was reverse-transcribed using
Table 1 Chemical structures and IC50 values in flavone, apigenin and luteolin on Hs578T, MDA-MB-231, and MCF-7 breast cancer cells
Lin et al. BMC Cancer  (2015) 15:958 Page 3 of 12
the Superscript First Strand synthesis system for conver-
sion to cDNA (Invitrogen, Carlsbad, CA). Primers and
probes for amplification and detection were selected
from the Universal Probes Library (Roche, UK). The
primer sequences used were as follows: FOXO3a (for-
ward: acaatagcaacaagtataccaagagc, reverse: gactgtcgtc
agctgattcg), p21 (forward: gcgactgtgatgcgctaat, reverse:
tcgaagttccatcgctcac), and p27 (forward: ccctagagggcaagt
acgagt, reverse: agtagaactcgggcaagctg). Amplification
was performed in a LightCycler480 system (Roche, UK)
beginning with an initial heating at 95 °C for 10 min,
followed by 40 cycles of 95 °C for 15 s, 60 °C for
10 s, and 72 °C for 1 s. Gene expression levels were
determined using glyceraldehyde 3-phosphate dehydro-
genase as a control.
Western blot
Whole cell lysates were obtained by direct lysis of the
cells using an ice-cold Mammalian Protein Extraction
Reagent (M-PER, Pierce). Nuclear and cytoplasmic frac-
tionations were performed using the Nuclear and Cyto-
plasmic Extraction Kit (Pierce). Protein (20 μg) was
resolved by 10 % SDS-PAGE and electro-transferred
onto a polyvinylidene difluoride membrane. Western
blotting was performed according to standard methods,
using anti-cleaved-PARP, anti-p53, anti-cytochrome c,
anti-Akt, anti-phosphorylated-Akt (ser473), anti-FOXO3a,
anti-p21, anti-p27 and anti-β-actin antibodies (Cell
Signaling Technology). The membranes were devel-
oped using an enhanced chemiluminescence detection
system, horseradish peroxidase substrate (Millipore)
and an ImageQuant LAS-4000 Chemiluminescence and
Fluorescence Imaging System (FujiFilm).
Statistical analysis
For each study group, data were derived from at least
three independent experiments. Statistical analysis was
performed using a Student’s t-test or Chi-Square test to
compare differences in values between the control and
experimental groups. The results are presented as the
mean ± SD. P < 0.05 indicated a statistically significant
difference.
Results
Effects of flavone, apigenin and luteolin on cell viability
and apoptosis of breast cancer cells
To determine the effect of the flavone, apigenin, and
luteolin on MCF-7, Hs578T, MDA-MB-231 cancer
cells and on a non-tumorigenic MCF-10A cell, a MTS/
PMS assay was performed. The IC50 for flavone, api-
genin and luteolin on these cells are listed in Table 1.
Flavone, apigenin and luteolin exhibited lower cyto-
toxic effect on MCF-10A cells than MCF-7, Hs578T
and MDA-MB-231 cells (Table 1). Flavone, apigenin,
and luteolin showed a concentration-dependent effect
on the cell viability of MCF-7, Hs578T, and MDA-MB-
231 cells (Fig. 1a, b, and c). Cell viabilities were signifi-
cantly decreased treating with 12.5–100 μM flavone,
apigenin, and luteolin for 72 h. Long-term effects of
flavone, apigenin, and luteolin on the growth of breast
cancer cells, were further assessed by colony formation
assay. After 21 d of treatment with flavone, apigenin,
and luteolin the colony numbers were suppressed by
2- to 3-fold (Fig. 1d, e).
To delineate the mechanisms of action of flavone, api-
genin and luteolin in breast cancer cells. Cell cycle ana-
lyses were performed using flow cytometry (Fig. 2a, b,
and c). Flavone induced arrest at G1 phase in Hs578T
and MDA-MB-231 cells, and at the G2-M phase in
MCF-7 cells. Treatment with apigenin and luteolin in-
duced arrest at G2-M and S phases in Hs578T and
MDA-MB-231 cells and at S phase in MCF-7 cells.
Thus, although all three compounds inhibited the
growth of Hs578T, MDA-MB-231, and MCF-7 cells,
their regulatory effects on the cell cycle differed.
We further examined the cyclin B, and cyclin D1
markers for G1, G2-M, and S phase arrest in the MCF-7
cells. Consistent with the observation that the flavone,
apigenin, and luteolin arrested MCF-7 cell cycle at the
G2-M or S phase, the expression levels of cyclin B and
cyclin D1 were reduced after treatment with these com-
pounds for 24 and 48 h (Fig. 2d).
The induction of apoptosis by flavone, apigenin, and
luteolin was detected by Hoechst 33342 staining (Fig. 2e, f).
Treatment with flavone, apigenin and luteolin in-
creased the number of apoptotic cells in MCF-7,
Hs578T, and MDA-MB-231 breast cancer cells. In
addition, western blot analysis in MCF-7 cells revealed
that the expression of p53 increased and that PARP
was cleaved to its intermediate forms (Fig. 2g). The ac-
tivation of PARP indicated an induction of the intrinsic
apoptosis pathway by the flavone, apigenin and luteo-
lin. Treatment with these compounds also increased
the release of cytochrome c into the cytosol of MCF-7
cells (Fig. 2g).
Flavone, apigenin and luteolin inhibited cell motility
To examine cell proliferation and migration, scratch
wound migration assays were conducted. Flavone, api-
genin and luteolin effectively reduced the migration of
MCF-7 cells into the wounded area (Fig. 3a, b). To ob-
tain further details, cell migration was measured in real
time, and treatment with flavone, apigenin, and luteolin
decreased the migration ability of MCF-7 cell (Fig. 3c).
These results confirm that flavone, apigenin, and luteolin
directly inhibit MCF-7 cell migration, ruling out the in-
fluence of proliferation on cell motility.
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Flavone, apigenin, and luteolin activate FOXO3a, which
is associated with a change in the signal transduction
pathway
We further determined the effect of flavone, apigenin,
and luteolin on the expression of FOXO3a, a transcrip-
tion factor and tumor suppressor, in the three cancer
cell types. Treatment of Hs578T, MDA-MB-231, and
MCF-7 cells with flavone, apigenin, and luteolin for 24 h
led to an increase in the expression RNA levels of
FOXO3a (Fig. 4a). To investigate whether flavone, api-
genin and luteolin affect the FOXO3a expression in
breast cancer cells, we performed western blot analyses
on the nuclear and cytoplasmic fractions of MCF-7 cells
treated with the IC50 concentrations of flavone, apigenin,
and luteolin for 48 h. We found that these compounds
increased the expression of FOXO3a in all the cells
(Fig. 4b).
FOXO3a is downstream target of Akt. Akt kinase
regulates breast cancer proliferation and survival [35].
Inhibiting Akt phosphorylation modulates the activities
of FOXO3a and subsequently affects cell proliferation,
apoptosis, and differentiation [36]. We therefore ex-
amined the roles of flavone, apigenin, and luteolin in
Akt signaling. Akt was predominantly phosphorylated
Fig. 1 Effects of flavone, apigenin and luteolin on cell viability of MCF-7, Hs578T and MDA-MB-231 breast cancer cells. a MCF-7, b Hs578T, and c
MDA-MB-231 cells were cultured in 96-well plates and treated with varying concentration of flavone, apigenin and luteolin (12.5–100 μM) for 72 h as
indicated. Cell viability was assessed with a MTS/PMS ((3-(4,5-dimethylthiazol-2-yl)-5-(3-carboxymethoxyphenyl)-2(4-sulfophenyl)-2H-tetrazolium, inner
salt)/phenazine methosulfate) assay. d Effects of treatment with IC50 concentrations (Table 1) of flavone, apigenin, and luteolin on for 21 d on colony
formation in MCF-7 cells. e Quantification of colony numbers from colony-forming assays of untereated MCF-7 cells (control) and cells treated with
flavone, apigenin, and luteolin. Results are the mean ± standard deviation of three independent experiments. P < 0.05 is considered as statistically
significant. Symbols: *: P < 0.05; #: P < 0.01; ★: P < 0.001
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in control cells, whereas Akt phosphorylation in cells
treated with flavone, apigenin, and luteolin for 48 h
showed a marked decrease which was consistent with
the decreased expression levels of FOXO3a protein
(Fig. 4c, d).
We found that all three flavones suppressed Akt
phosphorylation and increased FOXO3a expression.
Akt inhibits of p21 and p27 promoter activity through
reduction of FOXO3a expression [36–38]. Previous
studies have suggested that anti-cancer drugs up-
regulated p21 and p27, and this effect may play an im-
portant role in drug-induced cell cycle arrest in human
cancer. Therefore, we examined the expression of the
proteins p21 and p27, which are known targets of
FOXO3a in MCF-7 cells (Fig. 5). The results indicated
the flavone, apigenin, and luteolin induced upregulation
of FOXO3a, which subsequently induced the expres-
sion of p21 and p27. To confirm this finding, parallel
cell cultures were treated with flavone, apigenin, and
luteolin, and found an increase in p21 and p27 mRNA
levels (Fig. 5a). This finding suggests that the increased
expression levels of p21 and p27 observed in the western
blot analyses (Fig. 5b–d) resulted from an increase in
transcription. These results are consistent with our ob-
servation of alterations in PI3K/Akt, FOXO3a, p21, and
p27 expression levels after treatment with flavone,
Fig. 2 Flavone, apigenin, and luteolin induced cell cycle arrest and apoptosis in human breast cancer cells. a MCF-7, b Hs578T, and c MDA-MB-231 cells
were treated with the IC50 concentrations (Table 1) of flavone, apigenin, and luteolin for 24 h prior to cell cycle analysis by propidium iodide staining. The
percentage of cells in each phase of the cell cycle (sub G1, G0/G1, G2/-M and S) is indicated. d The effects of flavone, apigenin, and luteolin on cyclin B
and cyclin D1 protein expression. Western blot analyses were performed on cell lysates form MCF-7 cells treated with the IC50 concentrations (Table 1) of
flavone, apigenin, and luteolin for 24 h. e Flavone, apigenin, and luteolin induced apoptosis in MCF-7, Hs578T and MDA-MB-231 breast cancer
cells as detected by Hoechst 33342 staining. The breast cancer cells were treated with the IC50 concentrations (Table 1) of flavone, apigenin.
and luteolin. f Quantification of Hoechst 33342 staining of untreated MCF-7, Hs578T and MDA-MB-231 cells (control) and cells treated with flavone,
apigenin, and luteolin. g Western blot analyses for cleaved-PARP, tumor p53, and cytochrome c in MCF-7 cells treated with the IC50 concentrations
(Table 1) of the flavone, apigenin and luteolin from 24 h. Results are the mean ± standard deviation of three independent experiments. P < 0.05 is
considered as statistically significant. Symbols: *: P < 0.05; #: P < 0.01; ★: P < 0.001
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apigenin, or luteolin, suggesting that the flavone
compound-mediated inhibition of cell proliferation and
apoptosis were mediated at least part by regulation of
the PI3K/Akt/FOXO3a/p27 signaling pathway.
Discussion
Despite recent advances in medicinal chemistry, intrin-
sic and acquired resistance to chemotherapy treatments
and the possibility of relapse present drawbacks in the
treatment of breast cancer [39]. Because of the clear
risks posed by chemotherapy, researchers worldwide
have started searching for natural products that have
better anti-carcinogenic activity without side effects. In
addition, we believe that long chemotherapy treatment
weakens the immunological defense system of the body
and leaves patients susceptible to other infections and
diseases. Radiation therapy is another treatment to
combat cancer but also shows several potentially harm-
ful side effects including weakened immune system and
the potential to induce carcinogenesis itself. Therefore,
there is an urgent need to develop chemoprevention
approaches for the prevention of cancer. Chemopreven-
tion is an important function area of oncology that
focuses on the prevention of cancer using natural or
synthetic agents. Recently, natural plant extracts and
compounds have received widespread attention because
of their potential beneficial effects on human health.
Natural compounds provide a wide array of potential
drug candidates for cancer therapy with various roles
and targets [40, 41]. Accumulating evidence indicates
that curcumin [15], quercetin [42], emodin [43], res-
veratrol [14] and wogonin [44] of natural origin in-
duce apoptosis and inhibition of cell proliferation in
multiple tumor cell lines including A549 lung cancer
cells, hepatoma HepG2 cells, MCF-7 breast cancer
cells and LNCaP prostate carcinoma cells. Flavonoids
are the most common polyphenolic compounds, as they
are ubiquitously present in foods of plant origin [45].
Many practitioners have used flavone compounds
to treat a wide variety of ailments, including cancer
[21, 23, 24, 46, 47]. Accumulating evidence indicates
flavone compounds have been shown to have anti-cancer
Fig. 3 Flavone, apigenin and luteolin inhibited cell motility. a Representative images showing wound healing assays for cells treated with flavone
(88 μM), apigenin (30 μM) or luteolin (43 μM) and an untreated control for 24 h. b Average number of cells that had migrated after 24 h. c Effects
of the flavone, apigenin, and luteolin on MCF-7 cells migration. MCF-7 cells were treated with the IC50 concentrations (Table 1) of flavone, apigenin,
and luteolin, and the real-time migration of the cells was measured using an xCELLigence system. The value of the open area at 0 h is 100 %. Results
are the mean ± standard deviation of three independent experiments. P < 0.05 is considered as statistically significant. Symbols: *: P < 0.05; #: P < 0.01;
★: P < 0.001
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and anti-proliferative activities in in vitro and in vivo
[48, 49]. In this study, we examined the mechanisms
by which flavone, apigenin and luteolin induced cyto-
toxicity in breast cancer cells. We have shown that fla-
vone, apigenin and luteolin induce cell cycle arrest and
apoptosis in breast cancer cells. The induction of cell
apoptosis occurs in response to various stresses, in-
cluding activation of p53 [50], which leads to its nu-
clear translocation and activation of targets such as
cyclin D1 and p21 that regulate the cell cycle and trigger
apoptosis [51, 52]. Our results indicate that the cell cycle
arrest of MCF-7 cells treated with three compounds may
be associated with the inhibition of cyclin B and cyclin
D1-mediated cell cycle-arrest responses. Therefore, fla-
vone, apigenin and luteolin may inhibit breast cancer cells
proliferation via cell cycle arrest and apoptosis.
The PI3K-Akt signaling pathway plays a vital role in
tamoxifen and cytotoxic chemotherapeutic drug resistance
Fig. 4 Flavone, apigenin, and luteolin activate FOXO3a, which is associated with a change in the signal transduction pathway. a Real-time PCR for
FOXO3a. HS578T, MDA-MB-231 and MCF-7 cells were treated with the IC50 concentrations (Table 1) of flavone, apigenin, and luteolin for 0 h (control)
and 24 h. b Western blot analyses of total FOXO3a in cytoplasmic and nuclear extracts isolated from MCF-7 cells treated with the IC50 concentrations
(Table 1) of flavone, apigenin, and luteolin for various time from 0 to 48 h. Loading controls: cytoplasmic, β-actin; nuclear, proliferating cell
nuclear antigen (PCNA). c Densitometric quantification of the FOXO3a expression from the western blot analyses. d MCF-7 cells were treated
with IC50 concentrations (Table 1) of flavone, apigenin, and luteolin for 0–48 h. Western blot analyses of the total protein kinase B (Akt) and
Ser-473-phosphorylated Akt (p-Akt) in cytoplasmic and nuclear extracts isolated from MCF-7 cells treated with the IC50 concentrations (Table 1)
of flavone, apigenin, and luteolin for 0–48 h. Loading control: β-actin. e Densitometric quantification of the Akt and Ser-473-phosphorylated
Akt expression from the western blot analyses. Results are the mean ± standard deviation of three independent experiments. P < 0.05 is considered as
statistically significant. Symbols: *: P < 0.05; #: P < 0.01; ★: P < 0.001
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[6, 7, 53], and enhanced Akt activity has been shown to
elevate resistance to tamoxifen and cytotoxic drugs by
promoting cell proliferation and survival [54]. Many
cancers acquired drug resistance by PI3K/Akt pathway
activation, which has been observed during the adminis-
tration of paclitaxel in breast cancer [55]. Our results
showed that flavone, apigenin and luteolin treatment sub-
stantially suppressed PI3K/Akt phosphorylation at Ser473
in MCF-7 cells.
Members of the forkhead class O (FOXO) family of
transcription factors are crucial for regulating various
physiological processes, including proliferation, me-
tabolism, cell differentiation, cell cycle arrest, DNA
repair and apoptosis [56]. FOXO3a are important
targets of PI3K/Akt signaling pathway [11]. The Akt
mediated phosphorylation of FOXO3a is known to
transport FOXO3a out of nucleus and retain FOXO3a
in the cytoplasm [57]. FOXO3a has also been shown
to regulate cell cycle arrest and apoptosis through the
activation of transcriptional targets such as p27 and p21
[36]. The nuclear localization of FOXO3a and its subse-
quent transcriptional activity were known to be a prognosis
marker for breast cancers [9]. Our results demonstrated
that treatment of breast cancer cells with flavone, apigenin,
and luteolin for 12 h led to an inhibiting Akt activation
and increasing the expression levels of FOXO3a, which
subsequently increase the expression levels of p27 and p21
to inhibit the proliferation of breast cancer cells.
Fig. 5 Flavone, apigenin and luteolin regulate the expression of the cyclin-dependent kinase inhibitors p21 and p27 through the Akt-FOXO3a
signaling axis. a Real-time PCR for p21 and p27 expression in untreated MCF-7 cells (control) and cell treated with the IC50 concentrations
(Table 1) of flavone, apigenin, and luteolin for 0 and 24 h. b Western blot analyses of total p21 in cytoplasmic and nuclear extracts isolated
from MCF-7 cells treated with the IC50 concentrations (Table 1) of flavone, apigenin, and luteolin from 0 to 48 h. c Densitometric quantification
of the p21 expression from the western blot analyses. d Western blot analyses of total p27 in cytoplasmic and nuclear extracts isolated from
MCF-7 cells treated with the IC50 concentrations (Table 1) of flavone, apigenin and luteolin for 0–48 h. e Densitometric quantification of p27
expression from western blot analyses. Loading control (B and C): cytoplasmic, β-actin: nuclear proliferating cell nuclear antigen (PCNA). Results are the
mean ± standard deviation of three independent experiments. P< 0.05 is considered as statistically significant. Symbols: *: P< 0.05; #: P< 0.01; ★: P< 0.001
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Metastasis is complex processes and accounts for
the death of most cancer patients. In wound healing
assay, we found that treatment of the flavone, apigenin
and luteolin suppressed MCF-7 cells migration. Inhi-
biting Akt signaling reduced the migration and inva-
sion of gastric cancer cells [58], which may be due to
up-regulation FOXO3a. In renal cancer cells, FOXO3a
has been identified as a key factor in metastasis. Over-
expression of FOXO3a in renal cancer cells could
inhibit tumor metastasis [59]. Flavone, apigenin and
luteolin inhibit breast cancer cells migration was
through inhibiting Akt activation and increasing FOXO3a
expression.
Epidemiologic and clinical studies suggest that higher
intake of plant flavonoids can prevent cancer through
their interaction with various genes and enzymes [60].
Our study demonstrated that these three compounds
suppressed cell proliferation in human breast cancer
cells, in part, by acting on the Akt/FOXO3a/p27 sig-
naling pathway. Flavone, apigenin, and luteolin also
inhibited the proliferation of Hs578T, MDA-MB-231
and MCF-7 cells by promoting cell cycle arrest, cell
apoptosis and inhibiting cell migration and invasion.
These effects were associated with FOXO3a activation.
These compounds may thus reduce the risk of carcino-
genesis by affecting the Akt/FOXO3a/p27 signaling
pathway and serve as chemopreventive agents (Fig. 6).
Conclusions
Collectively, our study findings suggests that flavone,
apigenin, and luteolin have chemopreventive properties
against breast cancer, and these compounds are useful as
potential preventive or therapeutic agent in the manage-
ment of human breast cancer.
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